Evaluation of Soluble Epoxide Hydrolase (s-EH) Inhibitor in Patients With Mild to Moderate Hypertension and Impaired Glucose Tolerance

• Status: Completed
• Trial end date: 2009-11-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine the safety and efficacy of AR9281, a novel s-EH enzyme inhibitor, in improving glucose metabolism and blood pressure in patients with impaired glucose tolerance and mild to moderate hypertension.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Arete Therapeutics
• Treatments: 1-(1-acetyl-piperidine-4-yl)-3-adamantan-1-yl-urea

Criteria

Inclusion Criteria:

• mild to moderate hypertension

• naive to antihypertensive medication or on two or less antihypertensive medications

• impaired glucose tolerance

• mild obesity

Exclusion Criteria:

• Diagnosis of Type 1 or Type 2 diabetes

• History of severe heart failure

• AST, ALT levels more than twice the normal range